LUNG - רווח נקי למניה (EPS TTM) Pulmonx Corp.

Pulmonx Corporation (LUNG) relies on patent protection and FDA certification, creating significant barriers to entry for competitors. The annual net income per share illustrates this resilience, where the -1.01 mark indicates the current yield level. Efficiency is further evidenced by the automation of assembly shops and the implementation of ESG environmental standards across logistics and polymer recycling.
LUNG (Pulmonx Corp.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

To select high-quality assets, an investor requires an objective assessment of a business's real profitability. This indicator calculates annual net profit per share, excluding the impact of capital dilution from secondary offerings. For Pulmonx Corporation (LUNG), with its patent-protected Zephyr technologies, such a metric confirms the effectiveness of monetizing complex medical barriers. Analyzing the trend of rolling earnings per share allows for the timely detection of the impact of debt load.